The prognostic and therapeutic potentials of CTLA-4 in hematological malignancies.
Mohammad SadeghiAtefeh KhodakaramiArmin AhmadiMehrdad FathiJamshid Gholizadeh NavashenaqHamed MohammadiMehdi YousefiMohammad Hojjat-FarsangiAli Akbar Movasaghpour AkbariFarhad Jadidi-NiaraghPublished in: Expert opinion on therapeutic targets (2023)
According to the recent literature, CTLA-4 is overexpressed in different HMs, which is correlated with poor survival, while it is associated with better a prognosis in Chronic Lymphocytic Leukemia (CLL). Targeting CTLA-4 in Acute Myeloid Leukemia (AML), Sezary Syndrome (SS), Hodgkin's Lymphoma (HL), and so on, is helpful. While this is not recommended and may even be harmful in multiple myeloma (MM) and CLL. Also, it seems that certain CTLA-4 gene polymorphisms are efficient factors in the course of HMs. Future studies may broaden our knowledge regarding the role of CTLA-4 in HMs.